Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 combinations in advanced gastric or gastroesophageal junction adenocarcinoma (Phase II, open-label)
ChiCTR2500110933Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zeprumetostat in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Objective Response Rate (ORR) per RECIST v1.1 and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500110933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110933.